The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma

Published:2024-04-12 Issue:5-6 Volume:25 Page:249-257
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Lai Shufei¹²³,Luo Shaohong²³,Huang Qingwen¹²³,Lin Shen²³,Huang Xiaoting²³,Xue Honglin⁴,Cai Yijun¹²³,Xu Xiongwei²³,Weng Xiuhua²³^ORCID

Affiliation:

1. School of Pharmacy, Fujian Medical University, Fuzhou, 350108, China

2. Department of Pharmacy, the First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China

3. Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fujian Province, Changle, 350212, China

4. Department of Pharmacy, The 909th Hospital, School of Medicine, Xiamen University, 363000, China

Funder

The Joint Funds for the Innovation of Science and Technology, Fujian Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14622416.2024.2344438

Reference24 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Current treatment and recent progress in gastric cancer

3. Advanced gastric cancer: Current treatment landscape and future perspectives

4. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

5. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP